NCT04716361 is a clinical trial in Femoropopliteal Artery Occlusion, sponsored by First Affiliated Hospital of Zhejiang University.

Who is sponsoring NCT04716361?

NCT04716361 is sponsored by First Affiliated Hospital of Zhejiang University.

What condition does NCT04716361 study?

NCT04716361 studies Femoropopliteal Artery Occlusion.

Is NCT04716361 still recruiting?

NCT04716361 is currently status unknown. Last updated 22 February 2023.

Last reviewed 2023-02-22 · How we verify

NCT04716361

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Outcome of Endovascular Therapies in Chronic Femoropopliteal Occlusive Disease With Severe Calcification

Status unknown Last updated 22 February 2023

What this trial tests

trial in Femoropopliteal Artery Occlusion in 600 participants. Status unknown.

Timeline

10 December 2020

Primary endpoint
30 June 2023

31 December 2024

Quick facts

Lead sponsor	First Affiliated Hospital of Zhejiang University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	600
Start date	10 December 2020
Primary completion	30 June 2023
Estimated completion	31 December 2024
Sites	1 location across China

Conditions studied

Femoropopliteal Artery Occlusion — all drugs for Femoropopliteal Artery Occlusion →

Sponsor

First Affiliated Hospital of Zhejiang University

Who can join

18 and older, any sex, with Femoropopliteal Artery Occlusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, multicenter, real world, observational study, which aims at evaluating the safety, efficacy and economic cost of endovascular treatments for endovascular therapies in chronic femoropopliteal occlusive disease with severe calcification. It is estimated that 400 subjects diagnosed with chronic femoropopliteal occlusive disease with severe calcification and receive endovascular treatments will be enrolled in eight centers nationwide from January 2021 to December 2022. All the subjects will be under follow-up for two years. There is no restriction on the endovascular techniques. The primary outcomes include the technical success rate of each endovascular techniques and the reintervention rate driven by lesions' clinical symptoms.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Protocol of the evolution study: A prospective, multicenter, observational study evaluating the effect and health economics of endovascular treatment in patients with moderate and severe calcification of femoropopliteal artery.
Pan J, Guo L, Fang X, Feng Z, et al · · 2022 · cited 2× · PMID 36330013 · DOI 10.3389/fcvm.2022.1039313
Endovascular Treatment for Calcified Femoropopliteal Peripheral Artery Disease and Risk Factor Identification: Two Year Outcomes of the Evolusion Study.
Wang B, Xu Y, Yu X, Sun S, et al · · 2026 · cited 1× · PMID 41052588 · DOI 10.1016/j.ejvs.2025.10.002

Verify or expand the search:

Other recruiting trials for Femoropopliteal Artery Occlusion

Currently open trials in the same condition.

NCT04826705 — A Study of Endovascular Treatment of Femoropopliteal Arterial Occlusive Lesion With Drug-Coated Balloon · active not recruiting

Other First Affiliated Hospital of Zhejiang University trials

Trials by the same sponsor.

NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
NCT07510867 — 18F-FAPI PET/CT and MRI in Gastric Cancer · not yet recruiting
NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07468162 — Characteristic Electroencephalogram of General Anesthesia · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04716361 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Zhejiang University
Last refreshed: 22 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04716361.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing